News | Heart Valve Technology | March 01, 2019

Global Market for Transcatheter Treatments to Double in Next Five Years

Benefits of open-heart repair alternative are pumping strong growth

Global Market for Transcatheter Treatments to Double in Next Five Years

March 1, 2019 — When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter treatments, a minimally invasive surgical procedure in which a replacement valve is inserted without requiring patients to undergo open heart surgery. The transcatheter treatment global market is expected to double in a few years according to a new BCC Research report, due to several factors. These include:  

  • An expanding geriatric population;
  • Higher prevalence of chronic diseases;
  • Increasing diagnoses of heart valve disease;
  • Adoption of transcatheter techniques; and
  • Positive reimbursement and other healthcare reforms.

The global market for transcatheter treatment was valued at roughly $4 billion in 2018 and is expected to reach approximately $8 billion in 2023 at a compound annual growth rate (CAGR) of 14.8 percent, according to the BCC Research report “Transcatheter Treatment: Procedures and Heart Valve Market.”

Top competitors in the industry include: Abbott Laboratories, Boston Scientific Corp., Medtronic, Vascular Innovations Co. Ltd., Valcare Inc. and others.

Highlights from the report include:

  • Market segment analysis. The market has shifted from open surgical repair to transcatheter procedures due to their various advantages. The transcatheter aortic valve segment leads the global market, followed by transcatheter mitral valve devices.
  • Market region analysis. The U.S. is expected to maintain dominance in the global market of transcatheter treatment devices, reaching $4.8 billion by 2023 and increasing at a CAGR of 15.5 percent.
  • Global market drivers. Transcatheter procedures are being increasingly accepted worldwide because they offer more comfort to high-risk patients and have advantages in terms of operative risk and patient recovery time compared with open surgical repair.

“Transcatheter treatment has created a great buzz,” said Ritu Thakur Dangi, the report’s author. “Transcatheter mitral valve repair and replacement is a relatively new and niche segment globally, but it is growing and has strong potential due to a robust product pipeline. Now that transcatheter aortic valves have been successfully launched, unmet needs in mitral valve repair represent a future growth opportunity.”

The report also explores some significant barriers to market growth, including:

  • High costs of transcatheter heart valves;
  • Lack of awareness about valvular disease;
  • Stringent regulatory approval procedures;
  • Lack of healthcare infrastructure in developing regions;
  • The need for lifelong surveillance of artificial valves;
  • Procedure-associated risks and complications; and
  • Device recalls.

For more information: www.bccresearch.com

Related Content

Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is a walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Overlay Init